PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE

May 1, 2006, 00:00
10.1016/S1098-3015(10)64685-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)64685-2/fulltext
Title : PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64685-2&doi=10.1016/S1098-3015(10)64685-2
First page :
Section Title :
Open access? : No
Section Order : 93
Categories :
Tags :
Regions :
ViH Article Tags :